| Trial ID: | L2701 |
| Source ID: | NCT00990444
|
| Associated Drug: |
Insulin In Dextran Matrix
|
| Title: |
A Two Part Study of Peroral Insulin in Type 2 Diabetes
|
| Acronym: |
ORA2
|
| Status: |
SUSPENDED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Insulin in Dextran Matrix
|
| Outcome Measures: |
Primary: Identification of the lowest dose of oral insulin in dextran matrix that produces a significant lowering of post-prandial blood glucose., 6 hours | Secondary: To establish the dose(s) when administered in a multi-dose fashion that lowers plasma glucose levels versus placebo in patients with Type 2 diabetes, 8 days
|
| Sponsor/Collaborators: |
Sponsor: Bows Pharmaceuticals AG
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-09
|
| Completion Date: |
2010-12
|
| Results First Posted: |
|
| Last Update Posted: |
2010-10-05
|
| Locations: |
Karolinska Trial Alliance, Phase I Unit, Stockholm, Solna, Stockholm, 17176, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT00990444
|
